ClinicalTrials.gg
Active, not recruitingNCT05893225Updated Jun 24, 2025

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

A Phase 2 interventional study of Metformin Hydrochloride 850 mg Oral Tablet and Placebo in Multiple Sclerosis, Primary Progressive Multiple Sclerosis and Secondary-progressive Multiple Sclerosis, sponsored by University Hospital, Antwerp. Active, not recruiting at 5 sites in Belgium. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-24.

Primary conditionMultiple Sclerosis, Chronic ProgressiveRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Chronic Progressive
Why
  1. The study's listed conditions name Multiple Sclerosis, Chronic Progressive, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Antwerp · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Multiple Sclerosis, Chronic Progressive with a site in Belgium — 3 open to participants now, 7 under way, 5 of them phase 3. Multiple Sclerosis, Chronic Progressive · Belgium.

Planned enrollment
13th of 17
120 · median 769
Started
2023
the only one that year
Phase 2
Only one
of the 17
Registered
14th of 17
by date
Lead sponsor
1 of 17
University Hospital, Antwerp

Among the 17 studies in Multiple Sclerosis, Chronic Progressive with a site in Belgium, this one is the 13th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2, and was the 14th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

3 of the 17 studies in Multiple Sclerosis, Chronic Progressive with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Sclerosis, Chronic Progressive with a site in Belgium, or all of them as a file.
02

Study summary

This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination. Patients will continue their DMT treatment: metformin or placebo will be used as add-on study treatment.

Read the detailed description

Multiple Sclerosis (MS) is a chronic neuroinflammatory and neurodegenerative disease leading to focal and diffuse damage of myelin sheath and axons in the central nervous system (CNS). Pathophysiologically, the adaptive and innate immune system are involved in the inflammatory process, while mitochondrial dysfunction, oxidative stress and failure of remyelination are important mechanisms leading to chronic neurodegeneration. Despite currently available disease modifying treatments (DMTs) that target the immune system, patients continue to accumulate disability. Unfortunately, no neuroprotective or remyelinating agents are available to treat progressive MS. Hence, drugs to tackle disease progression in MS represent a major unmet need. In this respect, metformin is a very interesting drug to investigate in MS patients as a neuroprotective and remyelinating therapy. Several preclinical studies in animal models of MS have shown that metformin has both anti-inflammatory, neuroprotective and remyelinating properties. A clinical study with metformin in a limited sample of MS patients did not demonstrate significant adverse events. The aim of this clinical trial is to provide evidence for the neuroprotective and remyelinating effects of metformin (I) in MS patients (P) via measurement of clinical and MRI outcome measures (O), via a multicentre randomized placebo-controlled (C) clinical trial.

03

Conditions studied

  • Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Secondary-progressive Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Sclerosis
  • Metformin
  • Pathologic Processes
  • Demyelinating Autoimmune Diseases, CNS
  • Autoimmune Diseases of the Nervous System
  • Brain Remyelination
  • Neurodegeneration
04

In context

Multiple Sclerosis, Chronic Progressive Reclassified

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

This study's planned enrollment of 120 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.

Browse Multiple Sclerosis, Chronic Progressive studies →

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 243 studies on the registry; 66 are open to participants now.

Compared within Multiple Sclerosis, Chronic Progressive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of non-active progressive Multiple Sclerosis (PPMS and SPMS), as evidenced by:

    1. the absence of relapses and new T2 lesions on brain MRI in the past year or longer (No Evidence of Disease Activity-2)
    2. progression of disability independent of relapses in the past 1-2 years or longer

    If progression is defined as one of the following, over the past 1-2 years or less, the patient can be included without additional review:

    • minimum increase in the EDSS of 1.0, or 0.5 from a baseline level of 2.0-5.0, and 5.5-6.0, respectively
    • ≥20% in the T25FW
    • ≥20% 9HPT
    • reduction of ≥4 points or a 10% worsening in the Symbol Digit Modality Test without concomitant depression or fatigue.

    If the investigator is in the opinion that the patient is clearly progressing, but not enough data are available to demonstrate this, a narrative needs to be provided, which will be judged by at least 2 members of the Trial Steering Committee, from a center that is not submitting the case for review.

  2. Age 18-70 years inclusive
  3. EDSS 2.0-6.5 inclusive
  4. Able to give (signed, written) and to adhere to study procedures
  5. Dutch/Flemish speaking (patient reported outcomes and questionnaires available in Dutch/Flemish)
  6. Stable use of Disease Modifying Treatment (DMT) or no treatment in the past year or longer
  7. Use of adequate measures in women of (WOCBP)

Exclusion criteria

Exclusion Criteria:

  1. A medical or neurological problem other than MS that is a cause of progressive or fluctuating gait dysfunction
  2. Diagnosis of diabetes mellitus or fasting glucose level of 126mg/dl or more; random glucose level of 200mg/dl or more; of 6.5% or more at screening
  3. Unable to complete T25FW
  4. Unable to undergo MRI
  5. Current major disease or disorder other than MS (e.g., active , significant renal insufficiency (estimated Glomerular Filtration Rate) \<60 mL/min/1.73 m2, end-stage cardiopulmonary disease, alcoholism, liver insufficiency with (aspartate aminotransferase) >3 times (ULN), chronic active infection etc.) that may interfere with study procedures and/or intake of study drug
  6. Pregnant or breast-feeding or planning pregnancy
  7. Use of an experimental therapy in the past 6 months
  8. Ongoing immune reconstitution therapy schedule (cladribine second course ended at least 12 months before inclusion, alemtuzumab second/last course at least 12 months before inclusion, Hematopoietic Stem Cell Transplantation at least 12 months before inclusion)
  9. Expected change in ongoing DMT or start of DMT if untreated
  10. Current use of metformin or known intolerance for metformin
  11. Known sensitivity to the active substance or to any of the listed in section 6.1 of the Summary of Product Characteristics.
  12. All forms of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis), diabetic precoma.
  13. Acute conditions where there is a risk of alteration of renal function, such as: dehydration, severe infection, shock occurring between screening and randomization.
  14. Chronic use of NSAID
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Treatment group

    The treatment group will receive Metformin Hydrochloride oral tablets 850mg tid or bid, during a maximum of 96 weeks.

    Drug: Metformin Hydrochloride 850 mg Oral Tablet

  • Placebo comparator
    Control group

    The control group will receive a matching placebo, during a maximum of 96 weeks.

    Drug: Placebo

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.

  • DrugPlacebo

    Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.

07

What researchers measure

Primary outcomes

  1. Change in walking speed

    Change in walking speed as measured by the Timed 25 Foot Walk (T25FW) between baseline and 96 weeks of treatment

    Time frame: From baseline to 96 weeks

Secondary outcomes

  1. Change in cognitive function

    Change in cognitive function as measured by Symbol Digit Modalities Test (SDMT) between baseline and 96 weeks of treatment

    Time frame: From baseline to 96 weeks

  2. Change in hand function

    Change in hand function as measured by Nine-Hole Peg Test (9HPT) between baseline and 96 weeks of treatment

    Time frame: From baseline to 96 weeks

  3. Change in EDSS

    Change in Expanded Disability Status Scale. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10.0 (death) and is determined based on functional system scores (FSS) that are assigned after a standardized clinical neurological examination.

    Time frame: From baseline to 96 weeks

  4. Change in brain volume

    Change in brain volume (whole brain volume and gray matter volume) from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

    Time frame: From baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

  5. Change in T2 lesion volume

    Change in T2 lesion volume from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

    Time frame: From baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

  6. Change in T1 lesion volume

    Change in T1 lesion volume from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

    Time frame: From baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

  7. Change in brain magnetic resonance imaging diffusion tensor imaging (MRI-DTI) metrics

    Change in brain MRI-DTI metrics from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

    Time frame: From baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

Other outcomes

  1. Change in quality of life measured by EQ-5D-5L

    Change in quality of life as measured by EuroQol 5-dimension, 5-level (EQ-5D-5L) questionnaire between baseline and 96 weeks of treatment. The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. This tool also has an overall health scale where the rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.

    Time frame: From baseline to 96 weeks

  2. Change in quality of life measured by MSIS-29

    Change in quality of life as measured by Multiple Sclerosis Impact Scale-29 between baseline and 96 weeks of treatment. The MSIS, is a 29-item patient-reported measure of the physical and psychological impacts of MS. Patients are asked to rate how much their functioning and well-being has been impacted over the past 14 days on a 4-point scale, from "Not at all" (1) to "Extremely" (4).

    Time frame: From baseline to 96 weeks

  3. Change in the Composite endpoint

    Change in the Composite endpoint as measured by Overall Disability Response Score (ODRS) between baseline and 96 weeks of treatment. The ODRS is based on changes in EDSS, T25FW and 9HPT. At each time point, in individual patients, the scores of the four components are summed, which leads to a total score ranging from +4 to -4. A positive ODRS score means that there is a disability improvement compared to baseline and a negative ODRS score means a disability worsening from baseline.

    Time frame: From baseline to 96 weeks

  4. Change in 2 minute walk test

    Change in 2 minute walk test between baseline and 96 weeks of treatment

    Time frame: From baseline to 96 weeks

  5. Change in number of susceptibility weighted imaging (SWI) lesions

    Change in number of SWI lesions from baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

    Time frame: From baseline to 48 weeks, from baseline to 96 weeks and from 48 to 96 weeks

  6. Change in caregiver strain index (CSI)

    Change in caregiver strain index from baseline to 96 weeks. It is a 13-question tool that measures strain related to care provision. There is at least one item for each of the following major domains: Employment, Financial, Physical, Social and Time.

    Time frame: From baseline to 96 weeks

  7. Health resource questionnaire

    This questionnaire is adapted from Kobelt et al. and will be used to generate data for health economic analysis.

    Time frame: From baseline to 96 weeks

08

Study locations

5 sites
09

References and documents

Publications

  • De Keersmaecker AV, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, D' Haeseleer M, Bjerke M, Roelant E, Lemmerling M, D'hooghe MB, Derdelinckx J, Reynders T, Willekens B. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial. Front Immunol. 2024 Feb 21;15:1362629. doi: 10.3389/fimmu.2024.1362629. eCollection 2024. PubMed 38680485 ↗

Individual participant data

Plan to share: Yes — Protocol section 14.9 Access to the Study Data describes this in detail.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After peer-reviewed publication of study protocol and clinical trial results

Access criteria: See protocol section 14.9 Access to the Study Data

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.

Of 25 phase 2 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2022
First posted
Jun 7, 2023
StartActual
Nov 23, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05893225
Collaborators
University Hospital, Ghent, Hasselt University, AZ Sint-Jan AV, Noorderhart Pelt, National MS Center Melsbroek
Responsible party
Sponsor
First posted
Jun 7, 2023
Start date
Nov 23, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 24, 2025

Study contacts

Barbara Willekens, MD, PhD
principal investigator · University Hospital, Antwerp

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion